Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Cardiovascular Intervention in LA-NSCLC
NCT04980716Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of perindopril, metoprolol, spironolactone and trimetazidine in Cardiotoxicity (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Overall survival at 2 years and The incidence of grade 2+ cardiotoxicity events at 2 years. Started Jun 2021; status: recruiting.
02
Drugs
perindoprilmetoprololspironolactonetrimetazidine
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT04980716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980716.